Novartis is consistently rated as having one of the industry’s most respected development pipelines, with more than 200 projects in clinical development, including 145 in the Pharmaceuticals Division, as of April 21, 2016.
Many of these projects, which include new molecular entities as well as additional indications and different formulations for marketed products, are for medicines that could significantly advance treatment standards for patients worldwide. This table provides an overview of selected projects in development.
For a detailed review of selected projects in confirmatory development, download the complete Novartis Pipeline (PDF 84 KB), as of December 31, 2015.
AMG 334 is not included in this view. AMG 334 is part of the global collaboration with Amgen to commercialize and develop neuroscience treatments.
Submission anticipated late 2016 or early 2017.
Submitted in US and EU in Q1 2016.
Submitted in US in Q1 2016.
Submitted in EU in Q1 2016.
Also known as Fovista® (pegpleranib) and E10030. This product is being developed by Ophthotech Corp. Ophthotech has licensed ex-US commercialization rights to Novartis under a Licensing and Commercialization Agreement.
This information was factually accurate on the date it was published. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date. For the latest information on the Novartis' pipeline, readers should visit the News and Investors sections of our website. This information constitutes forward-looking statements relating to Novartis AG's business, including express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products. Such forward-looking statements reflect the current views of Novartis AG regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any new products will be approved for sale in any market, or that any new indications will be approved for existing products in any market, or that such products will achieve any particular revenue levels. In particular, management's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulation generally; the Novartis Group's ability to obtain or maintain patent or other proprietary intellectual property protection, including the uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing and other political pressures; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.